P53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition

Journal of Investigative Dermatology

Volumn 132, Issue 2, 2012, Pages 356-364

  Ji, Zhenyu ^a   Njauw, Ching Ni ^a   Taylor, Michael ^a   Neel, Victor ^a   Flaherty, Keith T ^b   Tsao, Hensin ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; MITOGEN ACTIVATED PROTEIN KINASE; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; SELUMETINIB; SHORT HAIRPIN RNA;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; COPY NUMBER VARIATION; ENZYME INHIBITION; IN VITRO STUDY; INHIBITION KINETICS; MELANOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR SENSITIVITY; TREATMENT RESPONSE; TUMOR GROWTH;

EID: 84855921054     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.313     Document Type: Article

References (36)

1. Adjei AA, Cohen RB, Franklin W et al. (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26:2139-46
2. Albino AP, Le Strange R, Oliff AI et al. (1984) Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? Nature 308:69-72 (Pubitemid 14130934)
3. Albino AP, Vidal MJ, McNutt NS et al. (1994) Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res 4: 35-45 (Pubitemid 24127098)
4. Castresana JS, Rubio MP, Vazquez JJ et al. (1993) Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma. Int J Cancer 55:562-5 (Pubitemid 23328938)
5. Chapman PB, Hauschild A, Robert C et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-16
6. Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70:440-6
7. Davies H, Bignell GR, Cox C et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-54 (Pubitemid 34716871)
8. Haass NK, Sproesser K, Nguyen TK et al. (2008) The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 14:230-9 (Pubitemid 351378000)
9. Hocker T, Tsao H (2007) Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat 28:578-88 (Pubitemid 46744288)
10. Hocker TL, Singh MK, Tsao H (2008) Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest Dermatol 128:2575-95
11. Hussussian CJ, Struewing JP, Goldstein AM et al. (1994) Germline p16 mutations in familial melanoma. Nat Genet 8:15-21 (Pubitemid 24274055)
12. Ji Z, Flaherty KT, Tsao H (2010) Molecular therapeutic approaches to melanoma. Mol Aspects Med 31:194-204
13. Kamb A, Gruis NA, Weaver-Feldhaus J et al. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-40
14. Kamijo T, Zindy F, Roussel MF et al. (1997) Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91:649-59 (Pubitemid 27513656)
15. Kojima K, Konopleva M, Samudio IJ et al. (2007) Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells. Cancer Res 67:3210-9 (Pubitemid 46724859)
16. McDermott U, Sharma SV, Dowell L et al. (2007) Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci USA 104:19936-41
17. Miller AJ, Mihm MC Jr (2006) Melanoma. N Engl J Med 355:51-65
18. Muthusamy V, Hobbs C, Nogueira C et al. (2006) Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer 45:447-54
19. Oancea M, Mazumder S, Crosby ME et al. (2006) Apoptosis assays. Methods Mol Med 129:279-90
20. Padua RA, Barrass N, Currie GA (1984) A novel transforming gene in a human malignant melanoma cell line. Nature 311:671-3 (Pubitemid 14000661)
21. Pomerantz J, Schreiber-Agus N, Liegeois NJ et al. (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-23 (Pubitemid 28155311)
22. Roche HL (2009a) A study of R7112 in patients with advanced solid tumors. In: ClinicalTrials.gov [Internet] (2000). Bethesda, MD: National Library of Medicine (US). http://clinicaltrials.gov/show/NCT00559533. Accessed on 9 September 2009
23. Roche HL (2009b) A study of R7112 in patients with hematologic neoplasms. In: ClinicalTrials.gov [Internet] (2000). Bethesda, MD: National Library of Medicine (US). http://clinicaltrials.gov/show/NCT00623870. Accessed on 9 September 2009
24. Sarek G, Kurki S, Enback J et al. (2007) Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J Clin Invest 117:1019-28 (Pubitemid 46556758)
25. Secchiero P, di Iasio MG, Gonelli A et al. (2008) The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. Curr Pharm Des 14:2100-10
26. Shangary S, Wang S (2009) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49:223-41
27. Smalley KS, Contractor R, Haass NK et al. (2007) An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res 67:209-17 (Pubitemid 46142777)
28. Solit DB, Garraway LA, Pratilas CA et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358-62 (Pubitemid 43128863)
29. Tovar C, Rosinski J, Filipovic Z et al. (2006) Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 103:1888-93 (Pubitemid 43228788)
30. Tsao H, Goel V, Wu H et al. (2004) Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 122:337-41 (Pubitemid 38281053)
31. Tseng HY, Jiang CC, Croft A et al. (2010) Contrasting effects of nutlin-3 on TRAIL-and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells. Mol Cancer Ther 9:3363-74
32. van't Veer LJ, Burgering BM, Versteeg R et al., (1989), N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol, 9, 3114-6. (Pubitemid 19163079)
33. Vassilev LT, Vu BT, Graves B et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-8 (Pubitemid 38174664)
34. Verhaegen M, Bauer JA, Martin de la Vega C et al. (2006) A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res 66:11348-59 (Pubitemid 46009966)
35. Yang G, Rajadurai A, Tsao H (2005) Recurrent patterns of dual RB and p53 pathway inactivation in melanoma. J Invest Dermatol 125:1242-51
36. Zhang Y, Xiong Y, Yarbrough WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-34 (Pubitemid 28155312)